Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
AstraZeneca
Moodys
Express Scripts
McKinsey

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ricolinostat

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Ricolinostat?

Ricolinostat is an investigational drug.

There have been 8 clinical trials for Ricolinostat. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Acetylon Pharmaceuticals Incorporated, Dana-Farber Cancer Institute, and Regenacy Pharmaceuticals LLC.

There are sixteen US patents protecting this investigational drug and one hundred and twenty-eight international patents.

Recent Clinical Trials for Ricolinostat
TitleSponsorPhase
Ricolinostat in Patients With Diabetic Neuropathic PainRegenacy Pharmaceuticals LLCPhase 2
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic CholangiocarcinomaNational Cancer Institute (NCI)Phase 1
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic CholangiocarcinomaMayo ClinicPhase 1

See all Ricolinostat clinical trials

Clinical Trial Summary for Ricolinostat

Top disease conditions for Ricolinostat
Top clinical trial sponsors for Ricolinostat

See all Ricolinostat clinical trials

US Patents for Ricolinostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ricolinostat   Start Trial HDAC inhibitors for the treatment of diabetic peripheral neuropathy REGENACY PHARMACEUTICALS, LLC (Boston, MA)   Start Trial
Ricolinostat   Start Trial Methods of making protein deacetylase inhibitors ACETYLON PHARMACEUTICALS, INC. (Boston, MA)   Start Trial
Ricolinostat   Start Trial Combinations of LSD1 inhibitors for use in the treatment of solid tumors Oryzon Genomics, S.A. (Madrid, ES)   Start Trial
Ricolinostat   Start Trial Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof Acetylon Pharmaceuticals (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ricolinostat

Drugname Country Document Number Estimated Expiration Related US Patent
Ricolinostat Canada 3001879 2035-10-27   Start Trial
Ricolinostat European Patent Office 3368026 2035-10-27   Start Trial
Ricolinostat Japan 2018535965 2035-10-27   Start Trial
Ricolinostat World Intellectual Property Organization (WIPO) 2017075192 2035-10-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
AstraZeneca
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.